Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer, will present at the J.P. Morgan 2024 42nd Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET.

A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.

About Vir Biotechnology

Vir Biotechnology, Inc. is an immunology company focused on combining cutting-edge technologies to treat and prevent infectious diseases and other serious conditions. Vir has assembled two technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.

Media Carly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1 314-368-5189

Investors Sasha Damouni Ellis Executive Vice President, Chief Corporate Affairs Officer sdamouni@vir.bio

Vir Biotechnology (NASDAQ:VIR)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Vir Biotechnology Charts.
Vir Biotechnology (NASDAQ:VIR)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Vir Biotechnology Charts.